Morgan Stanley said in its upgrade of the lab company that it sees more upside in the stock due to the coronavirus.positioned to meaningfully benefit as market shifts to phase II of COVID-19 testing. While shares have outperformed since earnings, we see more room for upside. Our updated 2021 estimates are 12% above consensus. Raising price target to $139 and rating to OW.
"UBS said in its downgrade of the stock that it sees a more balanced risk/reward.has outperformed the SPX by 17% YTD and now largely discounts a scenario where 2021 and beyond returns to a normalized pre-COVID environment. We see risks to this view, particularly within the Medical Device and Pharma segments. Our new Revenue and EBIT estimates for 2021 and 2022 are 11% and 10% below our prior estimates and are now 2%+ below consensus.
Colombia Últimas Noticias, Colombia Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Fuente: CNBC - 🏆 12. / 72 Leer más »